CD8+-cell-mediated Suppression of Virulent Simian Immunodeficiency Virus During Tenofovir Treatment

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Apr 29

PMID 15113912

Citations 31

Authors

Koen K A Van Rompay

Raman P Singh

Bapi Pahar

Donald L Sodora

Casey Wingfield

Jonathan R Lawson

Marta L Marthas

Norbert Bischofberger

Affiliations

Soon will be listed here.

Abstract

The ability of tenofovir to suppress viremia in simian immunodeficiency virus (SIV)-infected macaques for years despite the presence of virulent viral mutants with reduced in vitro susceptibility is unprecedented in this animal model. In vivo cell depletion experiments demonstrate that tenofovir's ability to suppress viremia during acute and chronic infection is significantly dependent on the presence of CD8+ lymphocytes. Continuous tenofovir treatment was required to maintain low viremia. Although it is unclear whether this immune-mediated suppression of viremia is linked to tenofovir's direct antiviral efficacy or is due to independent immunomodulatory effects, these studies prove the concept that antiviral immune responses can play a crucial role in suppressing viremia during anti-human immunodeficiency virus drug therapy.

Citing Articles

Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.

Symmonds J, Gaufin T, Xu C, Raehtz K, Ribeiro R, Pandrea I Viruses. 2024; 16(6.

PMID: 38932264 PMC: 11209256. DOI: 10.3390/v16060972.

A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.

Scholz E, Cao Y, Kashuba A J Antimicrob Chemother. 2021; 76(11):2890-2893.

PMID: 34374767 PMC: 8783597. DOI: 10.1093/jac/dkab298.

Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Van Rompay K, Hassounah S, Keele B, Lifson J, Ardeshir A, Watanabe J J Virol. 2018; 93(2).

PMID: 30381490 PMC: 6321921. DOI: 10.1128/JVI.01189-18.

Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART).

Policicchio B, Sette P, Xu C, Haret-Richter G, Dunsmore T, Pandrea I PLoS One. 2018; 13(2):e0190908.

PMID: 29466356 PMC: 5821307. DOI: 10.1371/journal.pone.0190908.

Tackling HIV and AIDS: contributions by non-human primate models.

Van Rompay K Lab Anim (NY). 2017; 46(6):259-270.

PMID: 28530684 DOI: 10.1038/laban.1279.

References

Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson A . A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol. 2003; 77(8):5037-8. PMC: 152136. DOI: 10.1128/jvi.77.8.5037-5038.2003. View

Giavedoni L, Velasquillo M, PARODI L, Hubbard G, Hodara V . Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J Virol. 2000; 74(4):1648-57. PMC: 111639. DOI: 10.1128/jvi.74.4.1648-1657.2000. View

Rosenwirth B, ten Haaft P, Bogers W, Nieuwenhuis I, Niphuis H, Kuhn E . Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol. 2000; 74(4):1704-11. PMC: 111645. DOI: 10.1128/jvi.74.4.1704-1711.2000. View

Van Rompay K, Miller M, Marthas M, Margot N, Dailey P, Canfield D . Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000; 74(4):1767-74. PMC: 111653. DOI: 10.1128/jvi.74.4.1767-1774.2000. View

Lifson J, Rossio J, Arnaout R, Li L, Parks T, Schneider D . Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol. 2000; 74(6):2584-93. PMC: 111746. DOI: 10.1128/jvi.74.6.2584-2593.2000. View

Kaech S, Ahmed R . Immunology. CD8 T cells remember with a little help. Science. 2003; 300(5617):263-5. DOI: 10.1126/science.1084511. View

Margot N, Isaacson E, McGowan I, Cheng A, Miller M . Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr. 2003; 33(1):15-21. DOI: 10.1097/00126334-200305010-00003. View

Yasutomi Y, Reimann K, Lord C, Miller M, Letvin N . Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol. 1993; 67(3):1707-11. PMC: 237548. DOI: 10.1128/JVI.67.3.1707-1711.1993. View

Reimann K, Tenner-Racz K, Racz P, Montefiori D, Yasutomi Y, Lin W . Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol. 1994; 68(4):2362-70. PMC: 236713. DOI: 10.1128/JVI.68.4.2362-2370.1994. View

10.

Calio R, Villani N, Balestra E, Sesa F, Holy A, Balzarini J . Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res. 1994; 23(1):77-89. DOI: 10.1016/0166-3542(94)90034-5. View

11.

Villani N, Calio R, Balestra E, Balzarini J, De Clercq E, Fabrizi E . 9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res. 1994; 25(2):81-9. DOI: 10.1016/0166-3542(94)90098-1. View

12.

Van Rompay K, Otsyula M, Marthas M, Miller C, McChesney M, Pedersen N . Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995; 39(1):125-31. PMC: 162497. DOI: 10.1128/AAC.39.1.125. View

13.

Tsai C, Follis K, Sabo A, Grant R, Bischofberger N . Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis. 1995; 171(5):1338-43. DOI: 10.1093/infdis/171.5.1338. View

14.

Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N . Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995; 270(5239):1197-9. DOI: 10.1126/science.270.5239.1197. View

15.

Van Rompay K, Otsyula M, Tarara R, Canfield D, Berardi C, McChesney M . Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis. 1996; 173(6):1327-35. DOI: 10.1093/infdis/173.6.1327. View

16.

Van Rompay K, Cherrington J, Marthas M, Berardi C, Mulato A, Spinner A . 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother. 1996; 40(11):2586-91. PMC: 163581. DOI: 10.1128/AAC.40.11.2586. View

17.

Van Rompay K, Greenier J, Marthas M, Otsyula M, Tarara R, Miller C . A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother. 1997; 41(2):278-83. PMC: 163702. DOI: 10.1128/AAC.41.2.278. View

18.

Nowak M, Bonhoeffer S, Shaw G, May R . Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol. 1997; 184(2):203-17. DOI: 10.1006/jtbi.1996.0307. View

19.

Bonhoeffer S, Coffin J, Nowak M . Human immunodeficiency virus drug therapy and virus load. J Virol. 1997; 71(4):3275-8. PMC: 191463. DOI: 10.1128/JVI.71.4.3275-3278.1997. View

20.

Tsai C, Follis K, Beck T, Sabo A, Bischofberger N, Dailey P . Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses. 1997; 13(8):707-12. DOI: 10.1089/aid.1997.13.707. View